Last reviewed · How we verify

Noah Rosenberg, MD — Portfolio Competitive Intelligence Brief

Noah Rosenberg, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Neo-Synalar Cream Neo-Synalar Cream marketed Topical corticosteroid Glucocorticoid receptor Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  2. Al-Azhar University · 1 shared drug class
  3. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  4. Apotex Inc. · 1 shared drug class
  5. Astellas Pharma Inc · 1 shared drug class
  6. Astion Pharma A/S · 1 shared drug class
  7. AstraZeneca · 1 shared drug class
  8. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Noah Rosenberg, MD:

Cite this brief

Drug Landscape (2026). Noah Rosenberg, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/noah-rosenberg-md. Accessed 2026-06-10.

Related